NV-CoV-2-R / NanoViricides - LARVOL DELTA

Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19. (PubMed, PLoS One) - "Another drug LAGEVRIO™ (molnupiravir) though has not been approved yet by FDA but has been authorized on December 23, 2021, for emergency use to treat adults with mild-to moderate COVID-19 symptoms and for whom alternative COVID-19 treatment options are not clinically appropriate. Secondly, RDV is protected from plasma-mediated degradation in transit. All together, NV-CoV-2-R is the safest and efficient regimen against COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application (Issuer Direct) - "NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison to remdesivir...Even more striking was the finding that NV-CoV-2-R exceeded the effectiveness of remdesivir itself in these cell culture studies....The Company studied the effectiveness of NV-CoV-2, NV-CoV-2-R and remdesivir against two unrelated human coronaviruses: h-CoV-229E (229E), and h-CoV-NL63 (NL63)....The Company intends to report on the results of these studies in its pre-IND application to the US FDA to obtain guidance regarding human clinical trials for treatment of COVID-19 patients....Company is engaged in the preparation of clinical trial protocols and other activities that would be necessary for submitting an IND application to the US FDA."

Preclinical • Infectious Disease • Novel Coronavirus Disease

NANOVIRICIDES : Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) (Market Screener) - "...we are also developing another anti-coronavirus drug candidate, NV-CoV-2-R. This drug candidate is comprised of holding remdesivir inside our polymeric drug candidate NV-CoV-2 by a process known as encapsulation....We were able to achieve the important milestone of completing the creation of NV-CoV-2-R from NV-CoV-2 and remdesivir...We have initiated production of a large batch of NV-CoV-2 and of NV-CoV-2-R under cGMP-compliant conditions for human clinical trials."

Commercial • New molecule • Infectious Disease • Novel Coronavirus Disease

NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application (Streetinsider.com) - "The Company is preparing a pre-IND application...Rats treated with remdesivir formulated in SBECD (comparable to the FDA-approved Veklury® formulation of remdesivir) survived for only 7.5 days. The total dose of remdesivir was 90mg/kgBW for the remdesivir treated group, and it was 80mg/kgBW when encapsulated in the NV-CoV-2-R group. Thus compared to treatment with remdesivir, treatment with the Company's drug candidate NV-CoV-2 extended the lifespan by approximately four times more days. Further, treatment with the Company's other drug candidate NV-CoV-2-R extended the lifespan by approximately five times more days."

Preclinical • Infectious Disease • Novel Coronavirus Disease